h-1.1 - Act respecting Héma-Québec and the biovigilance committee

À jour au 3 juin 2022

Ce document a valeur officielle.

chapter H-1.1

Act respecting Héma-Québec and the biovigilance committee

2013, c. 11, s. 16.

CHAPTER I HÉMA-QUÉBEC

DIVISION I CONTINUATION AND NATURE

1. Héma-Québec, constituted on 26 March 1998 by letters patent issued under Part III of the Companies Act (chapter C‐38), is continued in accordance with the provisions of this Act.

1998, c. 41, s. 1.

2. Héma-Québec is a legal person not established for pecuniary gain.

Héma-Québec is not a mandatary of the State.

1998, c. 41, s. 2.

DIVISION II MISSION

3. The mission of Héma-Québec is to provide the health and social services institutions in Québec and the population with a sufficient supply of blood, blood products and blood components.

In the pursuit of its mission Héma-Québec shall, in particular,

(1)  develop and enforce strict quality and safety standards in order to earn the trust of the general public and of the recipients of the products it distributes;

(2)  recruit blood and plasma donors and work in partnership with those donors and volunteer blood donor clinic organizers;

(3)  assume responsibility for the collection of blood and plasma;

(4)  manage the records of blood and plasma donors in accordance with strict standards of accuracy, security and confidentiality;

(5)  process the products collected;

(6)  assume responsibility for the storage, distribution and management of provincial stocks;

(7)  supply, in particular to health and social services institutions, the blood, blood products and blood components required by those institutions;

(8)  at the request of the Minister of Health and Social Services or the Centre d’acquisitions gouvernementales, obtain, store and supply to the institutions the fractionated products or substitute products required by those institutions;

(9)  engage in research and development for the purpose of developing new methods, new technologies and new products that meet the needs of Québec’s health system;

(10)  maintain links to ensure collaboration and the exchange of information with counterpart organizations in Canada and elsewhere, in order to be informed of and share expertise;

(11)  work in close collaboration with the authorities of the Canadian supply service so as to enable each system to benefit from the services and products of the other if necessary;

(12)  exercise any other function related to the supply system that is entrusted to it by the Minister of Health and Social Services.

Héma-Québec is also assigned, with the necessary modifications, such duties and functions in connection with human milk, stem cells and any human tissue, as well as any other human biological product determined by the Government.

Héma-Québec shall carry out any other mandate related to the duties or functions described in the preceding paragraphs that is entrusted to it by the Government.

In pursuing its mission, Héma-Québec must manage its human, material, information, technological and financial resources effectively and efficiently.

1998, c. 41, s. 3; 2013, c. 11, s. 1; 2017, c. 21, s. 79; 2020, c. 2, s. 42.

4. Héma-Québec may, in exercising its functions, enter into an agreement according to law with a government other than the Gouvernement du Québec, a department of such a government, an international organization, or an agency or body of such a government or organization.

Héma-Québec may also accept gifts, bequests, subsidies or other contributions, provided that any attached condition is compatible with the exercise of its functions.

1998, c. 41, s. 4.

5. Héma-Québec must enter into an agreement with the Canadian supply service to exchange information on donors with a view to maintaining supply safety, in particular as regards the risk of product contamination.

1998, c. 41, s. 5; 2013, c. 11, s. 2.

DIVISION III ORGANIZATION

6. The head office of Héma-Québec shall be located at the place determined by the Government. Notice of the location and of any change in location of the head office shall be published in the Gazette officielle du Québec.

Héma-Québec may hold its meetings at any place in Québec.

1998, c. 41, s. 6.

7. The affairs of Héma-Québec are administered by a board of directors composed of 13 members appointed by the Government, including the chair of the board and the president and chief executive officer.

Ten of those members other than the chair of the board and the president and chief executive officer are identified with the following categories:

(1)  the associations representing product recipients;

(2)  (subparagraph repealed);

(3)  the product donors and volunteer donor clinic organizers;

(4)  the Collège des médecins du Québec;

(5)  the scientific research sector;

(6)  the business sector; and

(7)  the public health sector.

There must be at least one but not more than three of the members referred to in the second paragraph per category. They are appointed after consultation with the persons or sectors in that category.

The board must also include a person who is a member of the Ordre des comptables professionnels agréés du Québec, appointed by the Government after consultation with that professional order.

1998, c. 41, s. 7; 2002, c. 38, s. 4; 2013, c. 11, s. 3; 2022, c. 19, ss. 136 and 433.

8. No public servant within the meaning of section 1 of the Public Service Act (chapter F‐3.1.1) may be a member of the board.

1998, c. 41, s. 8.

9. (Repealed).

1998, c. 41, s. 9; 2013, c. 11, s. 4; 2022, c. 19, s. 137.

10. The president and chief executive officer shall act as the secretary of Héma-Québec.

1998, c. 41, s. 10; 2013, c. 11, s. 5; 2022, c. 19, s. 138.

11. (Repealed).

1998, c. 41, s. 11; 2022, c. 19, s. 139.

12. The quorum at meetings of the board of directors is a majority of its members, including the chair or, as the case may be, the vice-chair.

1998, c. 41, s. 12; 2022, c. 19, ss. 140 and 433.

13. The Minister may designate a member of the biovigilance committee to attend the meetings of the board of directors. That member is entitled to speak at the meetings.

1998, c. 41, s. 13; 2013, c. 11, s. 6; 2022, c. 19, s. 433.

14. The office of president and chief executive officer is a full-time position.

1998, c. 41, s. 14; 2013, c. 11, s. 17; 2022, c. 19, s. 141.

15. The president and chief executive officer may not, on pain of forfeiture of office, have a direct or indirect interest in an enterprise causing the president and chief executive officer’s personal interest to conflict with that of Héma-Québec. However, forfeiture of office is not incurred where the interest devolves to the president and chief executive officer by succession or gift, provided it is renounced or disposed of with dispatch.

Every other member of the board of directors having such an interest must, on pain of forfeiture of office, disclose the interest in writing to the board and withdraw from meetings while any matter relating to the enterprise in which the interest is held is being discussed or voted upon.

1998, c. 41, s. 15; 2013, c. 11, s. 17; 2022, c. 19, s. 433.

16. The board of directors shall fix the remuneration, employment benefits and other conditions of employment of the president and chief executive officer. The remuneration and employment benefits of the president and chief executive officer shall be submitted to the Government for approval.

The other members of the board of directors shall receive no remuneration, except in such cases, on such conditions and to such extent as the Government may determine. They are entitled, however, to the reimbursement of the expenses they incur in the performance of their duties, on the conditions and to the extent determined by the Government.

1998, c. 41, s. 16; 2013, c. 11, s. 17; 2022, c. 19, s. 433.

17. The board of directors may establish an executive committee composed of not fewer than five members of the board, including the chair and the president and chief executive officer, determine its functions and powers and fix the term of office of its members.

1998, c. 41, s. 17; 2013, c. 11, s. 17; 2022, c. 19, s. 433.

18. Héma-Québec may make by-laws concerning the exercise of its powers and its internal management.

The by-laws may, in particular, provide that absence from a specified number of meetings, in the cases and circumstances determined in the by-law, constitutes a vacancy.

1998, c. 41, s. 18.

19. The members of the personnel shall be appointed in accordance with the staffing plan and standards established by Héma-Québec by by-law.

Subject to the provisions of a collective agreement, Héma-Québec shall determine, by by-law, the standards and scales of remuneration, employee benefits and other conditions of employment of the members of its personnel in accordance with the conditions defined by the Government.

1998, c. 41, s. 19; 2000, c. 8, s. 151.

20. Héma-Québec may establish advisory committees to facilitate the execution of its mission, and determine the terms of reference of each committee and its rules of operation.

The members of such a committee shall receive no remuneration, except in such cases, on such conditions and to such extent as the Government may determine. They are entitled, however, to the reimbursement of the expenses they incur in the performance of their duties, on the conditions and to the extent determined by the Government.

The committees may hold their meetings at any place in Québec.

1998, c. 41, s. 20.

DIVISION IV FINANCIAL PROVISIONS AND REPORTS

21. The fiscal year of Héma-Québec ends on 31 March.

1998, c. 41, s. 21.

22. Not later than 30 June each year, Héma-Québec must file its financial statements with the Minister together with an annual management report for the preceding fiscal year.

The financial statements and the annual management report must contain all the information prescribed by the Minister.

1998, c. 41, s. 22; 2022, c. 19, s. 431.

23. The Minister shall table the financial statements and the annual management report in the National Assembly within 30 days of receiving them or, if the Assembly is not sitting, within 30 days of resumption.

1998, c. 41, s. 23; 2022, c. 19, s. 431.

24. The books and accounts of Héma-Québec shall be audited each year by the Auditor General, and whenever so ordered by the Government.

The report of the Auditor General must be submitted with Héma-Québec’s financial statements.

1998, c. 41, s. 24.

25. The operations of Héma-Québec shall be financed out of the gifts, subsidies and other contributions it receives, out of the revenues deriving, in particular, from the supply of its products to health and social services institutions and other bodies, and, where applicable, out of the proceeds of the sale of its assets.

Any surpluses are paid into the Consolidated Revenue Fund, unless a prior agreement between Héma-Québec and the Minister is entered into on the use of the surplus.

1998, c. 41, s. 25; 2013, c. 11, s. 7.

26. The Government may, on the terms and conditions it determines, guarantee the payment of the capital of and interest on any loan made by Héma-Québec and the performance of any of the obligations of Héma-Québec.

1998, c. 41, s. 26.

27. The Government may, on the terms and conditions it determines, authorize the Minister of Finance to advance to Héma-Québec any amount considered necessary for the pursuit of its mission.

1998, c. 41, s. 27.

28. The sums paid under section 26 or 27 shall be taken out of the Consolidated Revenue Fund.

1998, c. 41, s. 28.

29. (Repealed).

1998, c. 41, s. 29; 2020, c. 5, s. 120.

30. Héma-Québec may not construct, acquire, dispose of, convert or renovate an immovable without the Minister’s authorization, except in the cases, on the conditions and to the extent determined by the Government.

Héma-Québec may, however, rent an immovable without the Minister’s authorization, except in the cases, on the conditions and to the extent determined by the Government.

The Minister’s authorization is also necessary for any purchase or rental of equipment for an amount exceeding the thresholds determined by the Government, unless the equipment is required to ensure the safety of Héma-Québec products. In the latter case, Héma-Québec must, within 90 days after the purchase or rental, provide the Minister with proof that the purchase or rental was justified.

1998, c. 41, s. 30; 2013, c. 11, s. 8.

31. Héma-Québec must provide any information required by the Minister concerning its operations within the time and in the form specified by the Minister.

1998, c. 41, s. 31.

DIVISION V POWERS OF THE MINISTER

31.1. The Minister or a person authorized in writing by the Minister may conduct an inspection and, at any reasonable time, enter any premises under the responsibility of Héma-Québec to verify compliance with this Act or the regulations.

The inspector may

(1)  examine and make a copy of any document relating to Héma-Québec activities; and

(2)  demand any information relating to the application of this Act or a regulation and the production of any document connected with it.

A person having custody, possession or control of such documents must, on request, make them available to the inspector.

The inspector must, on request, produce a certificate of authorization signed by the Minister.

No proceedings may be brought against the inspector for acts in good faith in the performance of inspection duties.

2013, c. 11, s. 9.

31.2. The Minister may investigate or direct a person the Minister designates to investigate any matter relating to the application of this Act or the regulations.

For the purposes of such an investigation, the person who conducts an investigation has the powers and immunity conferred on commissioners appointed under the Act respecting public inquiry commissions (chapter C-37), except the power to order imprisonment.

2013, c. 11, s. 9.

31.3. No person may hinder a person in the performance of inspection or investigation duties, mislead or attempt to mislead that person by misrepresentation or deceptive statements, refuse to produce documents required by that person or omit or refuse, without good cause, to answer any question that may lawfully be asked.

2013, c. 11, s. 9.

31.4. Once the inspection or investigation is completed, the Minister may require Héma-Québec to submit an action plan to remedy the situation, if applicable.

2013, c. 11, s. 9.

32. The Minister may assume the provisional administration of Héma-Québec in the following cases:

(1)  if a permit that is necessary to the operations of Héma-Québec has been or is likely to be suspended or revoked, or has not been or is unlikely to be renewed;

(2)  if the Minister considers that Héma-Québec is engaging in practices or is tolerating a situation that may compromise the safety, quality or quantity of the products it distributes;

(3)  if the Minister considers that one or more of the members of the board of directors have committed a gross fault such as malfeasance, breach of trust or other misconduct, or if the board has been seriously remiss in the performance of the obligations imposed on it by law.

Where the Minister assumes the provisional administration of Héma-Québec, the powers of the members of the board of directors are suspended, and the Minister shall exercise all the powers of the board of directors.

1998, c. 41, s. 32; 2022, c. 19, s. 433.

33. After assuming the provisional administration of Héma-Québec, the Minister must file a preliminary report containing observations and recommendations with the Government as soon as possible.

Before filing the report, the Minister must give Héma-Québec an opportunity to present observations, and the Minister must append a summary of the observations to the report.

1998, c. 41, s. 33.

34. After receiving the Minister’s preliminary report, the Government may request that the Minister continue the provisional administration of Héma-Québec for a period not exceeding three months, or that the Minister terminate the provisional administration within the time it indicates.

Where the Government requests that the Minister continue the provisional administration, it shall indicate whether all or any of the powers normally exercised by the board of directors will be suspended and exercised by the Minister.

1998, c. 41, s. 34; 2022, c. 19, s. 433.

35. The Minister shall file a report with the Government as soon as the Minister finds that the situation referred to in section 32 has been corrected, or that it cannot be corrected before the end of the provisional administration.

After receiving a report from the Minister, the Government may take either of the steps provided for in section 34.

1998, c. 41, s. 35.

36. No person who assumes the provisional administration of Héma-Québec under the authority of the Minister may be prosecuted for anything done in good faith in exercising the person’s functions.

1998, c. 41, s. 36.

37. On the advice of the biovigilance committee, the Minister may require that Héma-Québec take certain specific steps to ensure the quality and safety of the products it distributes.

In the same manner, the Minister may, for the same reasons, require that Héma-Québec withdraw certain products and notify any persons to whom such products have been distributed as well as the Canadian supply service and any other counterpart organization with which Héma-Québec has business dealings, of the risk of contamination they present.

1998, c. 41, s. 37; 2013, c. 11, s. 16.

DIVISION VI DETERMINATION OF THE CONDITIONS GOVERNING THE SUPPLY OF PRODUCTS AND SERVICES

2013, c. 11, s. 10.

37.1. The price of the products and services provided by Héma-Québec to health and social services institutions is to be paid in full by the institutions. However, if the Minister considers it expedient, the Minister may pay all or part of the cost directly, in the manner agreed by the Minister and Héma-Québec.

2013, c. 11, s. 11.

38. (Repealed).

1998, c. 41, s. 38; 2017, c. 21, s. 80; 2020, c. 2, s. 43.

39. If, one month before the date fixed for the forwarding of the budgetary forecasts of Héma-Québec to the Minister, in accordance with the directives provided for in section 45.2 of the Financial Administration Act (chapter A-6.001), Héma-Québec and the designated body have not reached agreement, they must appoint a mediator to assist them in settling their dispute.

If, on the date fixed for the forwarding of the budgetary forecasts, the parties have not agreed on a mediator, or if they have not settled their dispute three months after that date, the Minister may require the parties to submit their dispute to arbitration.

The arbitration proceedings shall commence on the date of the Minister’s decision.

1998, c. 41, s. 39; 2020, c. 5, s. 121.

40. Each party must appoint an arbitrator within 10 days after the Minister’s decision, and such arbitrators must appoint a third arbitrator within 10 days after their appointment. Failing the making of such appointments by the parties or the arbitrators within the time limits stipulated, the Minister may apply to a judge of the Court of Québec to make the appointments, and the judge’s decision may not be appealed.

1998, c. 41, s. 40.

41. Articles 631 to 637 and 642 to 644 of the Code of Civil Procedure (chapter C‐25.01) apply to the arbitration, with the necessary modifications.

The arbitration award must be rendered within two months after the appointment of the third arbitrator.

1998, c. 41, s. 41; I.N. 2016-01-01 (NCCP).

42. All the conditions governing the supply of products, including the price of the products, must be fair and reasonable.

Where a dispute pertains to the price of a product, the arbitrators must have regard in particular to

(1)  the expenditure which they consider necessary to pay the costs of production, in particular costs relating to the recruitment of donors, product collection, analysis, processing, storage and distribution and an allowance for the depreciation of the equipment and capital property used;

(2)  the undepreciated research and development expenditures;

(3)  the fact that the objects of Héma-Québec do not include the making of a profit and that it must finance its operations in accordance with section 25.

1998, c. 41, s. 42.

43. The arbitration award may not be appealed, and Héma-Québec cannot impose different conditions on the health and social services institutions for the acquisition of its products.

1998, c. 41, s. 43.

CHAPTER II BIOVIGILANCE COMMITTEE

2013, c. 11, s. 16.

44. A biovigilance committee is hereby established under the name “Comité de biovigilance”.

1998, c. 41, s. 44; 2013, c. 11, s. 16.

45. The function of the biovigilance committee is to advise the Minister, as considered necessary by the Minister and not less than once yearly, on current risks relating to the use of blood, blood products and blood components and the use of substitute products.

The mandate of the biovigilance committee shall include examining any matter submitted to it by the Minister in connection with the blood supply system and giving the Minister its opinion within the time indicated by the Minister.

The Minister may assign the biovigilance committee similar functions with regard to human milk, stem cells, human tissues or organs and any other human biological product.

1998, c. 41, s. 45; 2013, c. 11, s. 12.

46. The biovigilance committee shall be composed of the following persons, appointed by the Minister:

(1)  one person from the public health laboratory known as Laboratoire de santé publique du Québec;

(2)  one person working in the public health departments of the agencies referred to in section 371 of the Act respecting health services and social services (chapter S-4.2) or in the public health department established by the regional council under section 63.3 of the Act respecting health services and social services for Cree Native persons (chapter S-5);

(3)  one medical epidemiologist;

(4)  one ethicist;

(5)  three medical haematologists practising in a health and social services institution;

(6)  three users of the health and social services system having an interest in the blood supply system;

(7)  one expert in the field of perinatal care.

The Minister may also appoint up to three other members to the committee if the Minister considers that their expertise would advance the work of the committee.

1998, c. 41, s. 46; 2002, c. 38, s. 5; 2005, c. 32, s. 308; 2013, c. 11, s. 13.

47. One person designated by Héma-Québec and two persons designated by the Deputy Minister of Health and Social Services shall attend the meetings of the haemovigilance committee and shall be entitled to speak at the meetings.

1998, c. 41, s. 47.

48. The members of the haemovigilance committee shall be appointed for a term not exceeding two years.

At the end of their term, the members of the haemovigilance committee shall remain in office until reappointed or replaced.

1998, c. 41, s. 48.

49. The Minister shall designate a chair and a vice-chair of the haemovigilance committee from among the members; the vice-chair shall chair the haemovigilance committee when the chair is absent or unable to act.

One of the persons designated by the Deputy Minister of Health and Social Services to attend the meetings of the committee shall act as the secretary of the committee.

1998, c. 41, s. 49.

50. The quorum at meetings of the haemovigilance committee is a majority of its members, including the chair or, where applicable, the vice-chair.

In the case of a tie-vote, the chair has the casting vote.

1998, c. 41, s. 50.

51. The haemovigilance committee may make by-laws concerning its internal management.

1998, c. 41, s. 51.

52. The fees and allowances of the members of the haemovigilance committee shall be fixed by the Government, as shall the fees of the consultants and experts consulted by the haemovigilance committee.

1998, c. 41, s. 52.

53. The Ministère de la Santé et des Services Sociaux shall pay the fees and allowances referred to in section 52. It shall also, within the scope of its resources, pay for the administrative support needed by the haemovigilance committee to carry out its work.

1998, c. 41, s. 53.

54. The haemovigilance committee shall provide the Minister with any information required by the Minister concerning its operations, within the time and in the form indicated by the Minister.

1998, c. 41, s. 54.

CHAPTER II.1 COMPENSATION FOR VICTIMS OF A HÉMA-QUÉBEC PRODUCT

2009, c. 45, s. 4.

54.1. In this chapter, unless the context indicates otherwise,

“bodily injury” means any physical or mental injury suffered by a victim, including death but excepting any adverse effects determined by regulation;

“Héma-Québec product” means any product distributed by Héma-Québec, except

(1)  when such a product is used for research or clinical trials, unless the Minister decides otherwise; or

(2)  when such a product is made from a human biological product determined by the Government and the Government has decided to exclude it from the compensation plan for victims;

“victim” means a person who received a Héma-Québec product, a person who contracted a disease from a person who received a Héma-Québec product, or a child conceived and born alive and viable of either of such persons or, if death occurs, the person who is entitled to a death benefit.

2009, c. 45, s. 4; 2013, c. 11, s. 14.

54.2. The Minister must compensate, regardless of liability, a victim of bodily injury caused by a defect in or contamination, by known or unknown pathogens, of a Héma-Québec product.

The medical act leading to the injury must have taken place in Québec.

2009, c. 45, s. 4.

54.3. Compensation under this chapter is the same as that provided for by the Automobile Insurance Act (chapter A-25) and its regulations, with the necessary modifications.

2009, c. 45, s. 4.

54.4. Entitlement to compensation is prescribed three years after the date on which the bodily injury becomes apparent.

However, if an injury becomes apparent gradually, the time limit runs from the day the injury first becomes apparent.

2009, c. 45, s. 4.

54.5. Compensation under this chapter stands in lieu of all rights and remedies against Héma-Québec, the members of its board of directors and its employees by reason of bodily injury.

However, in cases where it is not otherwise prohibited by law, the victim may institute civil proceedings against any other person liable for the bodily injury.

2009, c. 45, s. 4; 2022, c. 19, s. 433.

54.6. The Minister is subrogated by operation of law to the rights and actions of the victim against the person liable for the bodily injury up to the amount of the compensation paid by the Minister or of the capital representing the pension to be paid by the Minister.

The subrogation is prescribed three years after the date of the Minister’s decision to compensate the victim.

2009, c. 45, s. 4.

54.7. A claimant who believes he or she has been wronged by a decision of the Minister under section 54.2 or 54.3 may, within 60 days of the date of notification of the decision, contest the decision before the Administrative Tribunal of Québec.

2009, c. 45, s. 4.

54.8. A proceeding before the Administrative Tribunal of Québec does not suspend the payment of compensation.

2009, c. 45, s. 4.

54.9. The sums necessary for the purposes of this chapter are taken out of the Consolidated Revenue Fund.

2009, c. 45, s. 4.

54.10. The Minister may, by agreement, entrust to a public body the management of all or part of a compensation plan for victims of a Héma-Québec product.

2009, c. 45, s. 4.

54.11. The Government must, by regulation,

(1)  determine the conditions that must be met by a person claiming compensation under this chapter; and

(2)  determine which adverse effects are not bodily injuries.

2009, c. 45, s. 4.

54.12. This chapter applies to victims of Héma-Québec products administered after 27 September 1998. However, a victim whose right of recourse is prescribed when this section comes into force is not entitled to the compensation provided for in section 54.2.

2009, c. 45, s. 4.

CHAPTER III MISCELLANEOUS AND FINAL PROVISIONS

55. Except after obtaining the authorization of the Minister of Health and Social Services, no health and social services institution may use any blood, blood products or blood components, including fractionated products, except those supplied by Héma-Québec. However, the Minister may, in respect of the products determined by the Minister, grant such an exclusivity to another supplier.

The same rule may apply to substitute products or to any other product supplied by Héma-Québec, where so decided by the Minister.

1998, c. 41, s. 55.

56. The Minister of Health and Social Services is responsible for the administration of this Act.

1998, c. 41, s. 56.

57. (Repealed).

1998, c. 41, s. 57; 2013, c. 11, s. 18.

58. (Repealed).

1998, c. 41, s. 58; 2013, c. 11, s. 18.

59. (Repealed).

1998, c. 41, s. 59; 2013, c. 11, s. 18.

60. (Repealed).

1998, c. 41, s. 60; 2013, c. 11, s. 18.

61. (Repealed).

1998, c. 41, s. 61; 2013, c. 11, s. 18.

62. (Repealed).

1998, c. 41, s. 62; 1999, c. 40, s. 350; 2000, c. 42, s. 178; 2013, c. 11, s. 18.

63. (Repealed).

1998, c. 41, s. 63; 2013, c. 11, s. 18.

64. (Repealed).

1998, c. 41, s. 64; 2013, c. 11, s. 18.

65. (Repealed).

1998, c. 41, s. 65; 2013, c. 11, s. 18.

66. (Repealed).

1998, c. 41, s. 66; 2013, c. 11, s. 18.

67. (Repealed).

1998, c. 41, s. 67; 2013, c. 11, s. 18.

68. (Repealed).

1998, c. 41, s. 68; 2013, c. 11, s. 18.

69. (Repealed).

1998, c. 41, s. 69; 2013, c. 11, s. 18.

70. (Repealed).

1998, c. 41, s. 70; 2013, c. 11, s. 18.

71. (Repealed).

1998, c. 41, s. 71; 2013, c. 11, s. 18.

72. (Repealed).

1998, c. 41, s. 72; 2013, c. 11, s. 18.

73. (Repealed).

1998, c. 41, s. 73; 2013, c. 11, s. 18.

74. (Repealed).

1998, c. 41, s. 74; 2013, c. 11, s. 18.

75. (Amendment integrated into c. R-8.2, Schedule C).

1998, c. 41, s. 75.

76. (Omitted).

1998, c. 41, s. 76.

REPEAL SCHEDULE

In accordance with section 9 of the Act respecting the consolidation of the statutes and regulations (chapter R‐3), chapter 41 of the statutes of 1998, in force on 1 April 1999, is repealed, except section 76, effective from the coming into force of chapter H-1.1 of the Revised Statutes.